Related Experiment Videos
Protective effect of Tadenan on bladder function secondary to partial outlet obstruction
R M Levin1, J P Riffaud, F Bellamy
1Division of Urology, University of Pennsylvania 19104, USA.
The Journal of Urology
|April 1, 1996
Summary
Tadenan pretreatment protected rabbit bladders from contractile dysfunction caused by benign prostatic hyperplasia (BPH) obstruction. However, it did not reduce bladder mass increase due to obstruction.
Area of Science:
- Urology
- Pharmacology
Background:
- Benign prostatic hyperplasia (BPH) is a common condition causing lower urinary tract symptoms.
- Partial outlet obstruction leads to bladder hypertrophy and contractile dysfunction.
- Tadenan is a pharmaceutical agent used for BPH treatment.
Purpose of the Study:
- To investigate the effect of Tadenan pretreatment on bladder hypertrophy and contractile dysfunction induced by partial outlet obstruction in rabbits.
Main Methods:
- New Zealand rabbits underwent partial bladder outlet obstruction for two weeks.
- Rabbits were pretreated with varying doses of Tadenan (1, 10, 100 mg/kg/day) or vehicle.
- In vitro studies evaluated bladder contractile responses.
Main Results:
- Tadenan did not significantly reduce bladder mass increase following obstruction.
- Tadenan pretreatment demonstrated a significant protective effect on bladder contractile responses to stimulation.
Conclusions:
- Tadenan pretreatment effectively protects the bladder from contractile dysfunction associated with partial outlet obstruction.
- Tadenan's efficacy in reducing BPH-induced bladder mass requires further investigation.